Eye-Popping Upside $EYPT $CCLD and $ACDC Set the Stage—Here What Analysts Expect Next

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  06 May 2025
 

$ACDC Shares of ProFrac Holding are limping into Wednesday’s earnings report, down 35% over the past year and currently trading at $4.56. While the technicals paint a bleak picture—hovering below all major moving averages and sitting in a clear downtrend—analysts still see upside potential. With a 1-year target of $6.50, that’s a nearly 40% jump from current levels. But let’s be real: this is a "show me" story. The last earnings report saw an EPS miss and a 7% gain the next day, reminding us that guidance—not just earnings—can move the stock. If ProFrac delivers a surprise beat or outlines a bullish production forecast, shares could catch a short-term bid.

Upside Potential: +39.78%
Trend: Downtrend
Rating: Neutral

$ARIS With a 49.33% gain over the last 12 months, Aris Water has quietly become a top performer in the water infrastructure space. Heading into Tuesday's earnings, the stock trades at $25.52, and analysts see a target of $29.00, offering a 13.64% upside. The last earnings miss didn’t stop shares from ripping +20% the next day, a clear sign that the market appreciates its long-term fundamentals. While the neutral rating suggests tempered expectations, the technical strength and positive trend set ARIS apart from more volatile small caps.

Upside Potential: +13.64%
Trend: Sideways
Rating: Neutral

$CCLD CareCloud crushed the tape Tuesday, surging +22% to $2.14 after posting a fourth consecutive quarter of net income. Adjusted EPS missed by a few cents, but analysts are unfazed. With a DCF-based price target of $5.00, shares have a potential upside of 133.6%. Management reiterated its 2025 guidance and laid out a clear path to margin expansion and revenue growth. Add to that a growing healthcare IT sector and undervalued peers trading at richer multiples, and you’ve got a compelling re-rating story.

Upside Potential: +133.6%
Trend: Sideways
Rating: Buy (Implied)

$COP ConocoPhillips is trading at $87.63, far off its 52-week high of $124.94. Despite a downtrend and tepid near-term action, the fundamentals are sturdy: a low PE of 11.23, $110B market cap, and stable earnings. While upside projections weren’t detailed, it's seen as one of the more undervalued plays in the energy space. That said, for traders seeking momentum or breakout setups, $COP may not be offering near-term fireworks.

Upside Potential: Moderate (not quantified)
Trend: Downtrend
Rating: Hold (Implied)

$DVN At $30.59, DVN offers an attractive PE of 6.71 and a decent yield, but technically it's caught in a persistent downtrend. Shares are below the 20, 50, and 200-day moving averages, and sentiment remains mixed. There's value here—but it’s not moving the needle in the short term. Unless crude rips higher or earnings surprise, DVN could remain rangebound.

Upside Potential: Unspecified
Trend: Downtrend
Rating: Hold (Implied)

$EYPT This is the moonshot. At $6.25, EyePoint trades more than 43% below its 52-week highs. But here's the kicker—analysts are targeting $29.33, implying a jaw-dropping +327.5% upside. Yes, the company continues to post negative EPS and the biotech sector is notoriously volatile, but investor sentiment can turn on a dime with one clinical catalyst or upbeat guidance. The Buy rating and massive target price make $EYPT one to watch closely heading into Wednesday’s earnings.

Upside Potential: +327.5%
Trend: Sideways
Rating: Buy

Bottom Line:
Among the names analyzed, $EYPT stands out with the most attractive near-term upside based on analyst targets. However, $CCLD is not far behind with a compelling value proposition and operational momentum. $ACDC is the dark horse—if earnings surprise to the upside, it could stage a strong rebound. Conservative investors might lean toward $ARIS for its stability and consistent performance, but for those chasing maximum upside, $EYPT is the clear high-risk, high-reward candidate.